Net price increases for seven drugs raised U.S. drug spending by $5.1 billion between 2017 and 2018 without evidence of improved safety or effectiveness, according to the first annual report by the Institute for Clinical and Economic Review on the costliest U.S. drug price increases unsupported by clinical evidence. For example, the average U.S. price for Humira, a drug used to treat chronic illnesses such as rheumatoid arthritis, increased 15.9% over the period after accounting for rebates and other concessions, raising spending on the drug by an additional $1.86 billion. “If new evidence emerges that shows a treatment may be more beneficial than what was previously understood, perhaps that new evidence could warrant some level of price increase,” said David Rind, M.D., chief medical officer for the independent research institute. “For seven of the nine drugs we reviewed, however, we found that the price increases lacked justification in new evidence.”

Related News Articles

Headline
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing on lowering prescription drugs prices, which focused on the drug supply chain.
Headline
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market.
Blog
A recent Health Affairs blog post (April 19) on hospital price transparency argues that chargemaster data can be confusing to consumers. We agree, and have…
Headline
The House Energy and Commerce Subcommittee on Health today held a hearing examining the increasing cost of prescription drugs in the Medicare program and ways…
Headline
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported…